vs

Side-by-side financial comparison of Lakeside Holding Ltd (LSH) and RYTHM, Inc. (RYM). Click either name above to swap in a different company.

RYTHM, Inc. is the larger business by last-quarter revenue ($10.7M vs $7.0M, roughly 1.5× Lakeside Holding Ltd). Lakeside Holding Ltd runs the higher net margin — -22.6% vs -127.6%, a 105.1% gap on every dollar of revenue. On growth, RYTHM, Inc. posted the faster year-over-year revenue change (242.0% vs 95.0%).

Lakeside Press was a Chicago publishing imprint under which the RR Donnelley Company produced fine books as well as mail order catalogs, telephone directories, encyclopedias, and advertising. The Press was best known for its high quality editions for the Chicago Caxton Club as well as the Lakeside Classics, a series of fine reprints.

RYTHM, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for rare genetic endocrine and metabolic disorders with high unmet medical needs. It primarily operates in the U.S. market, targeting pediatric and adult patient segments that lack standard effective treatment options.

LSH vs RYM — Head-to-Head

Bigger by revenue
RYM
RYM
1.5× larger
RYM
$10.7M
$7.0M
LSH
Growing faster (revenue YoY)
RYM
RYM
+146.9% gap
RYM
242.0%
95.0%
LSH
Higher net margin
LSH
LSH
105.1% more per $
LSH
-22.6%
-127.6%
RYM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LSH
LSH
RYM
RYM
Revenue
$7.0M
$10.7M
Net Profit
$-1.6M
$-13.6M
Gross Margin
27.2%
75.5%
Operating Margin
-21.3%
-121.5%
Net Margin
-22.6%
-127.6%
Revenue YoY
95.0%
242.0%
Net Profit YoY
18.7%
44.1%
EPS (diluted)
$-0.08
$-6.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LSH
LSH
RYM
RYM
Q4 25
$7.0M
$10.7M
Q3 25
$6.1M
$4.0M
Q2 25
$6.3M
$2.0M
Q1 25
$3.8M
$538.0K
Q4 24
$3.6M
$-7.5M
Q3 24
$4.1M
$1.9M
Q2 24
$3.0M
Q1 24
$2.6M
Net Profit
LSH
LSH
RYM
RYM
Q4 25
$-1.6M
$-13.6M
Q3 25
$-1.4M
$-10.7M
Q2 25
$-893.1K
$-7.4M
Q1 25
$-1.1M
$-1.6M
Q4 24
$-1.9M
$-24.4M
Q3 24
$-1.3M
$-18.7M
Q2 24
$-3.0M
Q1 24
$4.2M
Gross Margin
LSH
LSH
RYM
RYM
Q4 25
27.2%
75.5%
Q3 25
18.2%
34.0%
Q2 25
26.7%
33.4%
Q1 25
18.8%
16.7%
Q4 24
-1.2%
Q3 24
12.8%
11.6%
Q2 24
37.6%
Q1 24
6.4%
Operating Margin
LSH
LSH
RYM
RYM
Q4 25
-21.3%
-121.5%
Q3 25
-20.8%
-219.8%
Q2 25
-8.9%
-332.9%
Q1 25
-28.2%
-687.9%
Q4 24
-55.6%
Q3 24
-32.5%
-63.1%
Q2 24
-28.5%
Q1 24
13.6%
Net Margin
LSH
LSH
RYM
RYM
Q4 25
-22.6%
-127.6%
Q3 25
-22.2%
-263.8%
Q2 25
-14.2%
-360.4%
Q1 25
-28.2%
-302.2%
Q4 24
-54.1%
324.4%
Q3 24
-32.7%
-964.4%
Q2 24
-99.3%
Q1 24
163.0%
EPS (diluted)
LSH
LSH
RYM
RYM
Q4 25
$-0.08
$-6.78
Q3 25
$-0.09
$-5.33
Q2 25
$-0.11
$-3.74
Q1 25
$-0.14
$-0.83
Q4 24
$-0.26
$-24.26
Q3 24
$-0.18
$-17.28
Q2 24
$-3.16
Q1 24
$3.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LSH
LSH
RYM
RYM
Cash + ST InvestmentsLiquidity on hand
$1.6M
$32.2M
Total DebtLower is stronger
$2.4M
$80.6M
Stockholders' EquityBook value
$12.2M
$13.0M
Total Assets
$24.3M
$106.7M
Debt / EquityLower = less leverage
0.20×
6.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LSH
LSH
RYM
RYM
Q4 25
$1.6M
$32.2M
Q3 25
$4.5M
Q2 25
$5.0M
$41.0M
Q1 25
$1.5M
$24.4M
Q4 24
$1.1M
Q3 24
$2.7M
$267.0K
Q2 24
$57.0K
Q1 24
$99.0K
Total Debt
LSH
LSH
RYM
RYM
Q4 25
$2.4M
$80.6M
Q3 25
$2.4M
$90.6M
Q2 25
$1.4M
$40.6M
Q1 25
$774.2K
$10.6M
Q4 24
$784.8K
Q3 24
$589.9K
$6.2M
Q2 24
$4.6M
Q1 24
Stockholders' Equity
LSH
LSH
RYM
RYM
Q4 25
$12.2M
$13.0M
Q3 25
$7.0M
$11.7M
Q2 25
$2.8M
$21.0M
Q1 25
$749.8K
$26.8M
Q4 24
$1.6M
$28.1M
Q3 24
$3.6M
$5.5M
Q2 24
$8.5M
Q1 24
$-5.5M
Total Assets
LSH
LSH
RYM
RYM
Q4 25
$24.3M
$106.7M
Q3 25
$18.6M
$115.2M
Q2 25
$14.4M
$69.5M
Q1 25
$9.9M
$45.6M
Q4 24
$9.8M
$54.0M
Q3 24
$10.8M
$39.0M
Q2 24
$39.4M
Q1 24
$40.6M
Debt / Equity
LSH
LSH
RYM
RYM
Q4 25
0.20×
6.19×
Q3 25
0.35×
7.73×
Q2 25
0.48×
1.94×
Q1 25
1.03×
0.40×
Q4 24
0.48×
Q3 24
0.16×
1.13×
Q2 24
0.54×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LSH
LSH
RYM
RYM
Operating Cash FlowLast quarter
$-453.5K
$-3.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LSH
LSH
RYM
RYM
Q4 25
$-453.5K
$-3.0M
Q3 25
$-4.0M
$-5.4M
Q2 25
$-483.7K
$-8.4M
Q1 25
$-238.3K
$-6.7M
Q4 24
$-530.2K
$-5.3M
Q3 24
$-1.4M
$-1.4M
Q2 24
$-1.8M
Q1 24
$-3.0M
Free Cash Flow
LSH
LSH
RYM
RYM
Q4 25
Q3 25
Q2 25
$-497.4K
Q1 25
Q4 24
$-560.5K
Q3 24
$-1.4M
Q2 24
$-1.8M
Q1 24
$-3.0M
FCF Margin
LSH
LSH
RYM
RYM
Q4 25
Q3 25
Q2 25
-7.9%
Q1 25
Q4 24
-15.6%
Q3 24
-34.5%
Q2 24
-61.2%
Q1 24
-115.1%
Capex Intensity
LSH
LSH
RYM
RYM
Q4 25
Q3 25
Q2 25
0.2%
Q1 25
0.0%
Q4 24
0.8%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
LSH
LSH
RYM
RYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LSH
LSH

Transferred Over Time$4.6M65%
Distribution Of Pharmaceutical Products$2.4M35%

RYM
RYM

Nonlicensing Revenue$9.5M89%
Cultivation Business Discontinued Operations$1.2M11%

Related Comparisons